[Yunnan Baiyao: China's Phase I/IIa clinical trial of innovative nuclear drug INR101 injection completed the first subject enrolled] Securities Times e Company NewscrashofthetitansmobileOn May 24, the innovative nuclear drug INR101 injection was injected into Yunhe Pharmaceutical (Tianjin) Co., Ltd.(referred to as "Yunhe Pharmaceutical"), a wholly-owned subsidiary of Yunnan Baiyaocrashofthetitansmobile...
[Yunnan Baiyao: The first subject was enrolled in the Chinese Phase I/IIa clinical trial of Chuangxin Nuclear Drug INR101 Injection] Securities Times e Company News that on May 24, Yunhe Pharmaceutical (Tianjin) Co., Ltd.(referred to as "Yunhe Pharmaceutical") completed the enrollment and administration of the first healthy subject in the Phase I/IIa clinical trial of Chuangxin Nuclear Drug INR101 Injection at Beijing Friendship Hospital Affiliated to Capital Medical University. INR101 injection is an innovative chemical Class 1 radiologic diagnostic drug developed by Yunhe Pharmaceutical. It is suitable for PET imaging of PSMA positive lesions in prostate cancer patients.